Gsa Capital Partners LLP Allovir, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$0.72 - $0.82 $126,290 - $143,830	-175,403 Reduced 77.4%	51,224 $37,000
Q1 2024 May 03, 2024	BUY	$0.64 - $0.78 $11,421 - $13,919	17,846 Added 8.55%	226,627 $172,000
Q4 2023 Feb 16, 2024	BUY	$0.68 - $2.39 $141,971 - $498,986	208,781 New	208,781 $141,000
Q2 2023 Aug 14, 2023	SELL	$3.17 - $5.82 $79,297 - $145,587	-25,015 Reduced 53.24%	21,967 $74,000
Q1 2023 May 12, 2023	SELL	$3.94 - $7.05 $86,754 - $155,233	-22,019 Reduced 31.91%	46,982 $185,000
Q4 2022 Feb 13, 2023	SELL	$4.7 - $9.98 $40,532 - $86,067	-8,624 Reduced 11.11%	69,001 $354,000
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $93,234 - $198,434	22,575 Added 41.01%	77,625 $612,000
Q2 2022 Aug 09, 2022	SELL	$3.26 - $7.06 $124,258 - $269,098	-38,116 Reduced 40.91%	55,050 $215,000
Q1 2022 May 11, 2022	SELL	$6.75 - $13.52 $110,976 - $222,282	-16,441 Reduced 15.0%	93,166 $629,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $1.42 Million - $2.85 Million	109,607 New	109,607 $1.42 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.